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A B S T R A C T
Introduction: Many women with PKU are well-informed about the risks of maternal PKU but there are several
barriers to achieving satisfactory metabolic control before and during pregnancy. Many studies have docu-
mented the outcome of maternal PKU infants, but very little has been reported about the experiences of women
of reproductive age with PKU, particularly about their psychosexual development, pre-conception, pregnancy
and postnatal experience.
Methods: In the UK, in a subsection of an online questionnaire conducted by the National Society for PKU
(NSPKU) about living with PKU, women aged 18 years and over completed 9 closed questions about their pre-
conception, pregnancy and post-natal experiences and an open-ended question on their reproductive health.
Results: 300 women aged 18 years and over with PKU completed this questionnaire with 37% (n=111/300) of
women already having children. 56% (n=71/128) of pregnancies were planned and a further 18% (n=23/
128) of women had both planned and unplanned pregnancies. Most women (73%, n=200/273) expressed
concerns, fears and distress about pregnancy and two thirds of women who had at least one pregnancy stated
that having PKU made pregnancy more stressful and diﬃcult. 60% (n=164/273) were concerned that they may
cause harm to a baby, 58% (n=159/273) worried about their ability to manage a strict diet during pregnancy,
54% (n=147/273) had anxiety about their ability to maintain blood Phe within target range, and 48%
(n=132/273) feared having an unplanned pregnancy.
Postnatally, 48% (n=45/93) had low mood or sadness, 41% (n=38/93) were depressed, 34% (n=32/93)
felt unable to cope, 33% (n=31/93) said they could not manage their PKU and care for their baby, 14%
(n=13/93) struggled with child care needs and 4% (n=4/94) worried they might hurt themselves or their
baby through being unable to manage their diet.
Conclusions: Many women with PKU have unmet sexual and reproductive health needs. Pregnancy fears are
prominent from adolescence onwards and for some women overarching concerns about their ability to cope with
pregnancy led to a decision not to have children. Interventions are needed to reduce the psychological impact of
the risk of maternal PKU syndrome and assist with safe pregnancies. Post-natal experiences of women with PKU
give rise to concern.
1. Introduction
In maternal phenylketonuria (PKU), high blood phenylalanine (Phe)
levels during pregnancy have a teratogenic eﬀect on the developing
foetus which can result in intrauterine growth retardation, facial dys-
morphism, developmental delay, intellectual disabilities, microcephaly
and congenital heart disease (CHD) [1–7]. Strict metabolic control
before and throughout pregnancy reduces foetal risk if dietary control is
achieved before conception and maintained throughout pregnancy [8].
The European PKU Guidelines [9] state that treatment should com-
mence pre-conception for maternal PKU and it emphasises that
signiﬁcant eﬀort should be undertaken to avoid any unplanned preg-
nancies.
In women with PKU, much importance is placed on education and
eﬀective contraceptive methods so that women are in control of their
reproductive health and avoid unplanned pregnancies. The European
Guidelines [9] emphasise that all women with PKU of child-bearing
age, starting at menarche, must receive preconception counselling
about the risks of an unplanned pregnancy. They should receive de-
tailed counselling regarding family planning and understand the ad-
verse eﬀects on the foetus of elevated Phe levels. Education should
continue into adulthood. For teenage girls and women, it is likely to be
https://doi.org/10.1016/j.ymgmr.2018.09.008
Received 7 August 2018; Received in revised form 28 September 2018; Accepted 29 September 2018
⁎ Corresponding author at: Dietetic Department, Birmingham Women's and Children's Hospital, Steelhouse Lane, Birmingham B4 6NH, United Kingdom
E-mail address: anita.macdonald@nhs.net (A. MacDonald).
Molecular Genetics and Metabolism Reports 17 (2018) 64–68
2214-4269/ © 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license 
(http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
discussed at most PKU clinic appointments.
The dietary regimen pre-conception and during pregnancy is rig-
orous. Women initially commence a very strict low Phe diet, consume a
low Phe synthetic protein substitute three times daily, small, measured
quantities of natural protein according to tolerance, maintain adequate
energy intake to avoid catabolism (but need to avoid excess weight
gain), and monitor blood Phe levels at least twice weekly to maintain
concentrations between 120 and 360 μmol/L [4,9–12]. Women usually
attend a PKU clinic with experience of managing PKU. If women fail to
establish metabolic control in pregnancy, there is a National Health
Service (NHS) England commissioning policy that permits the use of the
drug sapropterin [13]. Sapropterin dihydrochloride, a synthetic for-
mulation of tetrahydrobiopterin (BH4) acts as a cofactor for phenyla-
lanine hydroxylase (PAH), increasing its activity by stabilisation of the
PAH tetramer [14]. It is eﬀective in 20 to 50% of patients, usually with
mild or moderate phenotype; and it may increase daily Phe tolerance by
two to three fold and improve metabolic control [9]. For women who
are sapropterin responsive and struggling with dietary management
and metabolic control, it should help alleviate some of the management
burden. Unfortunately, the NHS policy only permits testing with sa-
propterin at the time of pregnancy and the drug must stop at the end of
pregnancy.
Many women with PKU are well-informed about the risks of ma-
ternal PKU but there are several barriers to achieving satisfactory me-
tabolic control before and during pregnancy. The current policy of
maintaining dietary therapy throughout life may improve intellectual
functioning and alleviate some of the diﬃculties that women encounter
in returning to a low Phe diet. However, they are still likely to have
higher blood Phe levels than are considered safe at the time of preg-
nancy if not on a strict pre-conception diet ﬁrst. Some women may have
stopped or liberalized their diet in adulthood and may have diﬃculties
resuming a low Phe diet and tolerating the protein substitute [15].
Many studies have documented the outcome of maternal PKU in-
fants, but very little has been reported about the experiences of women
of reproductive age with PKU particularly about psychosexual devel-
opment, the pre-conception period, during pregnancy and postnatally.
A questionnaire that was developed by the UK National Society for PKU
(NSPKU) for patients and carers of children with PKU contained a sub-
section speciﬁcally written for women aged 18 years and over. We re-
port the results of this survey for women only.
2. Material and methods
An online questionnaire was voluntarily completed and submitted
by adults with PKU or parents/caregivers of children or adults unable to
complete the survey themselves. The survey was placed on the UK
NSPKU website, facebook and twitter account between 9th November
2017 to 31st January 2018. Additional promotion of the questionnaire
was conducted by the NSPKU at patient and family meetings. Only one
questionnaire was completed for each person with PKU.
The questionnaire was comprised of 61 questions, including single
choice, multiple choice and 4 open-ended questions on all aspects of
PKU. In a subsection of the questionnaire, women aged 18 years and
over completed 9 closed questions on pre-conception, pregnancy and
post-natal pregnancy experience and the following open-ended ques-
tion:
If there is anything else about your experience of being a woman with
PKU that you would like us to know and include? (Your answer may be
included in published materials but you will not be identiﬁed by name.)
The survey dataset was imported into ‘NVIVO v 11 pro’ software, a
programme for qualitative data analysis. There were 77 useable re-
sponses, and each one was created as a case in NVIVO (allowing re-
sponses to be ﬁltered by any characteristics or response which was
captured in the survey). The open-ended question was created as a
node, and the individual response within the question was read
separately and coded at a very ﬁne level of detail according to one or
more nodes created in response to emerging patterns in the data. Those
responding to this question were considered a distinct group as they
were questioned about experiences of being a woman with PKU and
their reproductive health and generated a set of accounts of living with
PKU in relation to fertility, pre-conception, pregnancy and post-natal
experiences.
2.1. Data cleaning
Age breakdown was carried out as a check on the validity of the
responses (i.e. to check that all responses were from adults) and com-
pared against a separate question about their age.
2.2. Analysis
Data was analysed using descriptive statistics only. The verbatim
extracts from the open questions were analysed using inductive the-
matic analysis [16] and NVIVO software. Recurring ideas, comments or
patterns were coded in and organised into a hierarchical pattern of
nodes with the top-level parent nodes being considered as themes.
Codes and themes were reviewed and reﬁned throughout the analysis
process (e.g. merging and splitting codes).
2.3. Ethics
Ethical consent was not sought as patient identiﬁable data was not
obtained. If names or hospitals were mentioned in verbatim abstracts,
these were removed. The purpose of the questionnaire was explained in
detail at the beginning of the document to respondents. It was clariﬁed
that the primary purpose of the document was to gain information to
support NHS considerations of future PKU treatments options in
England, Scotland, Wales and Northern Ireland. Potential respondents
were also advised that the NSPKU may publish data from the survey.
Women with PKU were considered to have given their consent by their
voluntary completion and submission of the questionnaire online.
3. Results
Three hundred women aged over 18 years with PKU completed this
questionnaire with 37% (n=111/300) of women already having
children (some had experienced more than one pregnancy). Fifty-six
per cent (n=71/128) of pregnancies were planned and a further 18%
(n=23/128) of women had both a planned and unplanned pregnancy.
Fourteen percent (n=36/263) of women had a miscarriage and 8%
(n=21/263) had more than one miscarriage.
Thematic analysis identiﬁed four themes: women's fears about
pregnancy prior to pregnancy, diet during pre-conception and preg-
nancy, challenges in the post-natal period, and support required and
information gaps.
3.1. Fears of pregnancy
Most women (73%, n=200/273) completing the survey expressed
concerns, fears and distress about pregnancy and two thirds of women
stated that having PKU made pregnancy more stressful and diﬃcult.
Sixty per cent (n=164/273) were concerned that they might cause
harm to their baby if they became pregnant, 58% (n=159/273)
worried about their ability to manage a strict diet during pregnancy,
54% (n=147/273) had anxiety about their ability to maintain blood
Phe within target range, and 48% (n=132/273) feared having an
unplanned pregnancy. Many women (84%, n=93/111) who had ex-
perienced pregnancy stated that they managed to maintain blood Phe
levels within target range for most of the time and indicated that it was
fear of damaging the foetus that inﬂuenced this level of control.
Some respondents expressed concern that as a woman with PKU it
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may be unsafe for them to have a baby (39% n=107/273), and some
worried about the level of care they could provide for a baby (16%,
n=43/273). Eight per cent (n=22/273) of women were too embar-
rassed to discuss pregnancy in clinic. Nine per cent (n=23/263) of
women said they had a pregnancy termination due to their PKU. From
the results of the thematic analysis, it was evident that some women
were so anxious about pregnancy and doing damage to the foetus or
how they would cope with caring for a baby, that they chose not to have
intimate sexual relationships. Some women stated they were unable to
foster close personal relationships due to pregnancy fears. Many iden-
tiﬁed they needed psychological help to discuss the psycho-sexual as-
pects of PKU, but this support was often unavailable to them and they
felt they could not share this with their medical team in a clinic en-
vironment. Also, the dichotomy of trying to reconcile maternal PKU
with religious, cultural, ethical or moral beliefs relating to contra-
ception and abortion was discussed.
Verbatim extracts from women's responses about their pregnancy fears (Theme: ‘F-
ears of Pregnancy’)
Pregnancy is a scary thought there is nothing I want more then to be a mum, but I am so
scared about becoming pregnant and hurting my child or myself that I have never had
sex as I'm so scared of there being an accident ……
I'm terriﬁed about becoming pregnant when not on pre-con. I don't believe that I would ever
be able to follow pre-con because I'm so bad at normal PKU diet. If I did have a child
on pre-con, I'd worry at how I would cope with life, PKU and a baby. I can't cope with
life on my own as it is now. I also worry at how my baby anxieties will aﬀect my
relationship as my partner is very keen to start a family. I am scared that I won't be
able to follow pre-con, and this will have an eﬀect on our relationship.
Fears about unplanned pregnancy has aﬀected my ability to develop relationships in that
way despite the knowledge that I can have a safe pregnancy if planned.
I think having been bombarded with information about pregnancy with PKU since around
the age of 12, (quite rightly), it almost has put me oﬀ having children. However, I think
this has been sub conscious. I had a couple of scares in my teens and early 20s, and it
was awful worrying so much!! With this condition, I have always been very clear that I
would seriously have to be desperate for a baby to go through it.
3.2. Experiences of dietary management pre-conception and during
pregnancy
The low Phe diet was described as diﬃcult by 78% (n=75/96) of
women in the pre-conception period and 59% (n=59/100) during
pregnancy.
This theme includes women's descriptions of their struggles with
dietary management, particularly the pre-conception diet, which added
to their stress of trying to conceive. During pregnancy some described
their anxiety if they had severe morning sickness, particularly when it
was prolonged and negatively impacted on metabolic control. Others
described their diﬃculties in eating an adequate calorie intake or ob-
taining satisfactory supplies of low protein foods from their GPs. Many
described that it was the fear of harming their unborn child that mo-
tivated them throughout pregnancy but then they described their joy at
giving birth to a ‘healthy’ child. This was an achievement they were
very proud of.
Verbatim extracts from women's responses about dietary management pre-concep-
tion and during pregnancy
Sticking to the PKU diet during pregnancy is not only extremely diﬃcult but stressful too, I
worry I can't eat enough and that the baby is going to be harmed because of that.
It is a shock to the system if you have not previously been on a strict diet to suddenly have to
monitor. To try to get your head around protein amounts and making sure you stay
within the levels as well as all other worries that come with pregnancy.
Fear motivated me to weigh and measure everything I drank and ate. I was directly resp-
onsible for the health of my child through the food choices I made. Determination made
it possible.
Preparation is the key, I had 13 years of planning and forethought with my second. Surprise
pregnancies are a little trickier, but motivation comes from the urge to protect. I had
quite a high tolerance to start with, a good understanding of my diet and lots of su-
pport. I see other women on 0 exchanges struggle throughout their pregnancy and my
heart goes out to them.
3.3. Post-natal challenges
In the post-natal period, 48% (n= 45/93) of women had low mood
or sadness, 41% (n= 38/93) were depressed, 34% (n=32/93) felt
unable to cope, 33% (n=31/93) said they could not care for their PKU
as well as their baby, and 14% (n=13/93) were unable to keep up
with their child care needs. Four per cent (n=4/93) worried that they
might hurt themselves or their baby. Fourteen per cent (n=14/102)
said that health or developmental problems in their children were
linked to PKU.
Women reported that in the post-natal period help from their health
care team was reduced and they felt isolated and less supported. Many
explained that they had no choice but to stop their low Phe diet as they
could not juggle child care and dietary management. Many were often
tired. Some struggled with breast feeding as they could not eat suﬃ-
cient calories on a low Phe diet in order to sustain this. They identiﬁed
how they needed more care from their health care providers at this
vulnerable time in their life.
Verbatim extracts from women's responses about post-natal experiences
Everyone and everything else comes before me and my PKU even though it should be the
other way around. In reality, my diet is the easiest thing to put to one side. My children,
my husband, work, running around looking after everyone and everything. I cannot
cope with the demands of day to day life and the time and emotional commitment
needed to maintain good blood levels. I do have good support from my husband but
that is not enough.
Went through a bad time after the baby was born had suicidal thoughts after the baby was
born. Needed psychiatric help at the time and needed watching. Baby did have PKU.
It is a constant struggle to feed my family and then make a separate meal for me.
My diet as a busy working mum takes a back seat a lot as I am busy ensuring my family are
cared for properly. It has been a real struggle to stay focused on diet since having both
my children and there is very little support out there.
The diet is stressful and time consuming and with two children to raise, a full-time job and
normal life stresses I just can't manage it successfully no matter how hard I try.
3.4. Support and information needs
Women described how they needed more psychology support to
help them deal with their anxiety about pregnancy and counselling for
their diﬃculties in forming intimate sexual relationships. They were
upset that some GP's, gynaecology and obstetric support teams ap-
peared to have limited knowledge about maternal PKU and that pro-
vided extra barriers to successful maternal PKU care. They also de-
scribed conﬂicting or lack of information regarding breast feeding and
the nutritional requirements of the mother with PKU.
Overall, 54% (n=143/263) of women with PKU said the UK NHS
should do more to help woman have a safe pregnancy with more sup-
port centred around their needs.
Verbatim extracts from women's responses about support needs
Maternal PKU is hard. It is a constant struggle to keep levels down and a constant worry
that your baby will be healthy. Many health care professionals whom you encounter
during pregnancy are not well enough educated on issues surrounding maternal PKU.
Most hospitals do not have much knowledge of PKU, so my local gynae team would qu-
estion things that would worry me on occasion (i.e. risk of PKU being passed on to my
baby), when logically I already knew of this through my Dietetic Team.
There should be more advice out there for women with PKU. No one understands, not the
consultant led units in the maternity units, not the GPs and no working places are made
aware.
4. Discussion
In maternal PKU, undoubtedly pregnancy is medically problematic,
with all pregnant women considered at risk. The health professional
focus is for the wellbeing of the foetus, with priority given to ensuring
that women achieve satisfactory blood Phe control with appropriate
dietary and medical support. Pregnancy should be associated with
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positive emotions, but the results of our survey indicated that maternal
PKU was a source of psychological morbidity for some women; raising
feelings of negativity, ambivalence, distress, and, in some cases, even
alarm.
Perception of pregnancy risk in maternal PKU aﬀected women's
behaviours and decision making. From the thematic analysis, they de-
scribed their vulnerability and expressed worry and uncertainty about
the outcome of pregnancies. They had anxieties about sex, struggled
with religious or moral beliefs about contraception and felt a ‘lack of
control over their fate’ during pregnancy. Some women did not perceive
dietary treatment to be manageable. Some were so scared of becoming
pregnant that they avoided sexual intimacy. When women were preg-
nant without having followed a pre-conception diet, they expressed
feelings of guilt, shock, and were often overwhelmed. Others who ex-
perienced pregnancy, described a heightened sense of anxiety, worrying
about every blood Phe result that was above or below the blood Phe
target range or were disturbed by any delay in blood Phe results. This
extra anxiety is concerning, as higher anxiety levels during pregnancy
have been associated with spontaneous abortions [17], preterm births
[18] and a higher level of postpartum depression [19].
Limited privacy in PKU clinics and lack of psychology support may
hinder patients from discussing sexual issues during their routine clinic
visit, prior to pregnancy. Women with PKU need to feel comfortable
about discussing pregnancy and contraception issues with their medical
teams and they commonly need reassurance about the choices that they
make. It is essential that they receive compassionate, sensitive health
care to discuss sexual health concerns. If support is received from their
community GP services, it is crucial they are fully briefed about the
risks of maternal PKU care. Genetic counselling is also recommended
for all reproductive-aged women with PKU and should include in-
formation on reproductive choices and family planning.
Another issue for some women with PKU was the lack of privacy
when they decide to consider pregnancy. They eﬀectively must make
their decision public through contact with the PKU clinic and imple-
ment immediate changes to their diets which are obvious to those
around them within the workplace. This “public declaration” of their
intention to have a child is considered intrusive and stressful by some
women, who may otherwise wish to keep this conﬁdential and it may
even result in their reluctance to initiate the diet prior to conception.
Many women described their diﬃcult battles with dietary man-
agement throughout pregnancy and the practical issues they en-
countered in implementing the strict PKU diet, although most women
said they maintained blood Phe levels within target range during
pregnancy. Some had inadequate and only intermittent access to low
protein foods and protein substitutes, particularly when trying to ad-
here to the strict diet in the pre-conception period. Some women found
the protein substitutes unpalatable, especially when they had preg-
nancy-related nausea and vomiting. Others struggled with calculating
Phe exchanges, eating adequate calories to prevent catabolism, limited
food choices and the extra time demands of this intensive diet and the
time required to attend frequent medical appointments. This interfered
with a woman's job and reduced her time available for paid work. It was
apparent that strong social support from a partner and family was a
critical factor in successful dietary management.
It was clear that many women stopped dietary management shortly
after child birth. They could not cope with the pressures of strict dietary
management and caring for their baby. Many described anxiety, de-
pression, tiredness and inability to focus well after the birth of the baby
and some described how they struggled with day to day child care.
Postpartum depression in the general population is known to adversely
aﬀect infant caregiving activities such as breast feeding and sleep
routines [20] and although it is not clear if the rate of postnatal de-
pression is higher in maternal PKU, there remains a possibility that this
may be exacerbated by higher blood Phe concentrations. It has been
shown that women who remain on dietary care post pregnancy are
likely to have fewer mental health issues and are better able to cope
with parenting [21] which in turn, has an important impact on the
cognitive outcome of their children. Furthermore, women needed gui-
dance about their own nutritional needs during breastfeeding whilst on
the PKU diet post birth. This education should be given as part of an-
tenatal care and women need practical support during breast-feeding.
None of the women said that they had been oﬀered the drug sa-
propterin which may help ease the pressures of dietary management
and improve blood Phe control during pregnancy, even though in
England, the NHS commission sapropterin for maternal PKU care. Data
suggests from case studies that sapropterin is safe in pregnancy and will
lower blood Phe concentrations in sapropterin responsive women [22].
The women in this survey found a strict low Phe diet particularly dif-
ﬁcult in the pre-conception period, and prescription of sapropterin to
responsive women may lessen the time required to achieve acceptable
blood Phe control prior to pregnancy. In addition, administration of
sapropterin in combination with dietary treatment in the post-natal
period may help women maintain blood Phe control within acceptable
limits, assist women to sustain breast feeding by helping them eat
suﬃcient calories, and lessen any PKU related symptoms due to poor
metabolic control.
4.1. Limitations
We did not collect any control data about female reproductive
health in the general population. We also did not collected data about
the reproductive health of women under 18. Our sample of women was
self-selected rather than by random, and it is unknown to what extent
the sample matches the characteristics of the general population. Whilst
it can be argued that only respondents with negative experiences of
PKU responded to this questionnaire, as many as 300 women aged
18 years and over responded, so it is likely this is a good representation
of views. Also, the questionnaire was completed independently of
health professionals, so it was easier for women to express their ‘true’
opinion.
5. Conclusions
In conclusion, this survey reports the reproductive health experi-
ences of 300 women aged 18 years and over with PKU. The results in-
dicate that pregnancy fears are prominent from adolescence and for
some women overarching concerns over their ability to cope with
pregnancy led to a decision not to have children. Healthcare providers
should be sensitive to the distress and anxiety experienced by many
women and they should be oﬀered psychology and other counselling to
discuss their anxieties and sexual health. Although health care profes-
sionals are very attentive with dietary care in the pre-conception and
pregnancy period, it is important that a high level of care continues
postnatally. At this time, women need more practical and emotional
support, so they are not left isolated to cope with parenting and their
dietary treatment. It is important that non-dietary treatments, when
appropriate, are oﬀered to ease the burden of managing maternal PKU
and that these are included in the pre-conception and post-natal care
package.
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